This clinical trial is focused on studying a type of lung cancer known as Non-Small Cell Lung Cancer (NSCLC). The study is specifically looking at cases where the cancer is locally advanced or has spread to other parts of the body, and where patients have a specific genetic feature called ROS1-positive. The trial will compare two treatments: Repotrectinib (TPX-0005) and Crizotinib. Both of these medications are taken orally in the form of hard capsules and are designed to target and inhibit certain proteins that help cancer cells grow.

The purpose of this study is to see how well these treatments work in preventing the cancer from getting worse. Participants in the trial will be randomly assigned to receive either Repotrectinib or Crizotinib. The study will monitor the participants over time to assess the effectiveness of the treatments in controlling the cancer. This will involve regular check-ups and assessments by medical professionals to track the progress of the disease and any side effects from the medications.

Throughout the study, the main focus will be on how long the participants can live without their cancer progressing, which is known as progression-free survival. Other aspects being studied include overall survival, how well the cancer responds to the treatment, and the duration of this response. The trial will also look at the time it takes for the treatment to start working and any potential side effects. The study aims to provide valuable information that could help improve treatment options for people with this type of lung cancer in the future.